Market closedADR

Adaptimmune Therapeutics/$ADAP

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Adaptimmune Therapeutics

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.

Ticker

$ADAP
Trading on

Industry

Biotechnology

Employees

449

ADAP Metrics

BasicAdvanced
$203M
Market cap
-
P/E ratio
-$0.30
EPS
2.20
Beta
-
Dividend rate
$203M
2.2
$2.05
$0.42
1.1M
3.092
2.907
43.683
49.18
-160.10%
-15.84%
-65.04%
1.335
2.11
2.13
-4.051
99.90%
-43.28%
183.26%
-31.79%

What the Analysts think about ADAP

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Adaptimmune Therapeutics stock.

ADAP Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ADAP Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ADAP

$

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Adaptimmune Therapeutics stock?

Adaptimmune Therapeutics (ADAP) has a market cap of $203M as of November 14, 2024.

What is the P/E ratio for Adaptimmune Therapeutics stock?

The price to earnings (P/E) ratio for Adaptimmune Therapeutics (ADAP) stock is 0 as of November 14, 2024.

Does Adaptimmune Therapeutics stock pay dividends?

No, Adaptimmune Therapeutics (ADAP) stock does not pay dividends to its shareholders as of November 14, 2024.

When is the next Adaptimmune Therapeutics dividend payment date?

Adaptimmune Therapeutics (ADAP) stock does not pay dividends to its shareholders.

What is the beta indicator for Adaptimmune Therapeutics?

Adaptimmune Therapeutics (ADAP) has a beta rating of 2.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.